Referrals to the LUCENTIS Co-pay Program
Co-pay programs provide direct financial assistance to patients to help with their co-pays, co-insurance or other out-of-pocket costs. If eligible commercially insured patients need assistance with their out-of-pocket costs, LUCENTIS Access Solutions can refer them to the LUCENTIS Co-pay Program.
To get started, call (855) 218-5307 or visit LUCENTISCopayProgram.com.
The LUCENTIS Co-pay Program is available only for commercially
insured patients. Patients using Medicare, Medicaid, Medigap,
Veteran's Affairs (VA), Department of Defense (DoD), TriCare or any
other government-funded program to pay for their medications are not
eligible. Patients who start utilizing their government coverage
during their enrollment period will no longer be eligible for the
program. It requires a valid, on-label prescription and cannot be
combined with any other rebate/coupon, free trial or similar offer
for the specified prescription. It is available only for a patient
(or their guardian) who is 18 years or older. It is not valid for
medications the patient receives for free or that are eligible to be
reimbursed by private insurance plans or other health care or
pharmaceutical assistance programs that reimburse the patient in
whole or in part for the medication. It is valid only for Genentech
products in the United States and US Territories. The LUCENTIS
Co-pay Program is not health insurance or a benefit plan. Please see
full terms and conditions at LUCENTISCopayProgram.com.
Important Safety Information & Indication
LUCENTIS® (ranibizumab injection) is indicated for the treatment of patients with:
- Neovascular (wet) age-related macular degeneration (wAMD)
- Macular edema following retinal vein occlusion (RVO)
- Diabetic macular edema (DME)
- Diabetic retinopathy (DR)
- Myopic choroidal neovascularization (mCNV)
Important Safety Information
LUCENTIS is contraindicated in patients with ocular or periocular infections or known hypersensitivity to ranibizumab or any of the excipients in LUCENTIS. Hypersensitivity reactions may manifest as severe intraocular inflammation.
WARNINGS AND PRECAUTIONS
Intravitreal injections, including those with LUCENTIS, have been associated with endophthalmitis, retinal detachment, and iatrogenic traumatic cataract.
Increases in intraocular pressure have been noted both pre-injection and post-injection with LUCENTIS.
Although there was a low rate of arterial thromboembolic events (ATEs) observed in the LUCENTIS clinical trials, there is a potential risk of ATEs following intravitreal use of VEGF inhibitors. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause).
Fatal events occurred more frequently in patients with DME and DR at baseline treated monthly with LUCENTIS compared with control. Although the rate of fatal events was low and included causes of death typical of patients with advanced diabetic complications, a potential relationship between these events and intravitreal use of VEGF inhibitors cannot be excluded.
In the LUCENTIS Phase III clinical trials, the most common ocular side effects included conjunctival hemorrhage, eye pain, vitreous floaters, and increased intraocular pressure. The most common non-ocular side effects included nasopharyngitis, anemia, nausea, and cough.
For additional safety information, please see LUCENTIS full prescribing information.
You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.